Alnylam Pharmaceuticals
ALNY
#378
Rank
A$91.11 B
Marketcap
A$689.70
Share price
-1.55%
Change (1 day)
76.66%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2025 : A$1.96 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is A$1.96 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2024-12-31A$2.08 B8.75%
2023-12-31A$1.91 B-1.24%
2022-12-31A$1.94 B40.99%
2021-12-31A$1.37 B103.01%
2020-12-31A$0.67 B56.2%
2019-12-31A$0.43 B919.01%
2018-12-31A$42.58 M10.82%
2017-12-31A$38.42 M-81.53%
2016-12-31A$0.20 B
2007-12-31A$7.72 M-33.3%
2006-12-31A$11.58 M14.67%
2005-12-31A$10.1 M8.61%
2004-12-31A$9.3 M272.07%
2003-12-31A$2.5 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Arrowhead Pharmaceuticals
ARWR
A$0.53 B-73.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
A$4.07 B 106.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A$1.88 B-4.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A$0.59 B-69.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A$2.1 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
A$48.20 B 2,347.32%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$38.43 B 1,851.26%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
A$25.70 B 1,204.83%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel